Skip to Main Content

A Phase II Trial of Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatment With an Immune Checkpoint Inhibitor

Conditions

Other Urinary | Urinary Bladder

Phase II

What is the purpose of this trial?

This study is designed to evaluate response and survival of treatment with the combination of pembrolizumab and ramucirumab in patients with progressive metastatic TCC after immune checkpoint inhibitor treatment.

  • Trial with
    Yale University
  • Start Date
    09/17/2020
  • End Date
    12/14/2022
Trial Image

For more information about this study, contact:

Matthew Piscatelli

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/21/2020
  • Study HIC
    #2000022801